The former president of AstraZeneca UK and the ABPI has given up big pharma to join biotech Redx. We speak to her about what prompted the change, how she thinks British life science will fare in the coming years, and how the UK can help smaller companies like Redx to thrive
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
New from PharmaTimes Media is the Medical & Scientific Excellence Awards.Highlighting this important area of work within the pharmaceutical industry, the awards are designed to recognise the outstanding achievements of medical and scientific professionals.
Despite the excitement surrounding T-cell therapy, CAR-T cells have fallen short in effectiveness against solid tumours. Oxfordshire-based Adaptimmune is one of the companies exploring T-cell receptors as a promising alternative. We spoke to the company’s chief technology officer Gwen Binder-Scholl about the science behind this challenging but exciting therapeutic area